Managing Post-Transplant Lymphoproliferative Disorders in Solid-Organ Transplant Recipients: A Review of Immunosuppressant Regimens

Author： Murukesan Vidhya  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.72, Iss.12, 2012-08, pp. : 1631-1643

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunosuppressants: Post-transplant lymphoproliferative disorder: case report

By  

Reactions Weekly, Vol. 1, Iss. 1229, 2008-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

II. Challenges in the management of post‐transplant lymphoproliferative disorder

By  

Hematological Oncology (Electronic), Vol. 33, Iss. S1, 2015-06 ,pp. : 96-99

John Wiley & Sons Inc

Access to resources Recommend Favorite

A CHOP regimen is effective for post-transplant lymphoproliferative disorders (PTLD) that have progressed after first-line therapy with rituximab

By  

Inpharma, Vol. 1, Iss. 1588, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Valganciclovir: therapeutic role in pediatric solid organ transplant recipients

By Yu Marie A   Park Jeong M  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 6, 2013-04 ,pp. : 807-815

Informa Healthcare

Access to resources Recommend Favorite

Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients

By Åsberg Anders   Rollag Halvor   Hartmann Anders  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1159-1166

Informa Healthcare

Access to resources Recommend Favorite